Matches in SemOpenAlex for { <https://semopenalex.org/work/W2410361430> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2410361430 endingPage "91" @default.
- W2410361430 startingPage "181" @default.
- W2410361430 abstract "The treatment of HCV correlated hepatitis is an important argument, because of the great incidence and prevalence of this disease. At the end of the Eighties, the IFN was the first substance used for HCV correlated hepatitis therapy. The IFN monotherapy with a dose of 3-6 MU for 6-12 months eradicates the infection in the 15% of cases, and cause an histological temporary improvement in a variable number of patients that keep the infection. In the following years, the research on evaluation of the efficacy of the recombinant interferons or interferons made with genetics engineering (IFN alpha 2a, IFN alpha 2b and IFN Consensus) has given results comparable with the results obtained with IFN alpha. Later, it started the experimentations with IFN associated to other substances, for example IFN-ribavirin combination therapy. The treatment IFN-Ribavirin eradicates the infection in 30% of the patients with the genotype 1b and in 60% with the genotype 2 or 3, while this treatment is less efficacious in the patients with the genotype 4. Recently, it started to use the PEG IFN. The pegylation is the combination of a polietylen-glicole molecule with the IFN molecule, so as to prolong its half-life and reduce the dose only one a week, with reduction of the collateral effects. Some studies has shown that the use of PEG-IFN in monotherapy could help the patients with advanced liver complaint. Successive studies are directed to show the efficacy of the PEG-IFN and ribavirin combination therapy. Recent researches put in evidence new substances, that could represent the future for HCV correlated hepatitis therapy. Between these substances we have to highlight the interleukin, the inhibitors of the viral multiplication and the inhibitors of IMPDH (Inosine monophosphate dehydrogenase). At the beginning of 2002 has made the improvement of HCV vaccine known. Actually, in the USA there are in progress human experimentations, and the production of gamma-globuline, that could be effective to prevent the infection." @default.
- W2410361430 created "2016-06-24" @default.
- W2410361430 creator A5001685490 @default.
- W2410361430 creator A5009943441 @default.
- W2410361430 creator A5033904438 @default.
- W2410361430 creator A5054282757 @default.
- W2410361430 creator A5073424133 @default.
- W2410361430 creator A5088390230 @default.
- W2410361430 date "2003-08-13" @default.
- W2410361430 modified "2023-09-27" @default.
- W2410361430 title "[Recent trends in the therapy of hepatitis C]." @default.
- W2410361430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12910808" @default.
- W2410361430 hasPublicationYear "2003" @default.
- W2410361430 type Work @default.
- W2410361430 sameAs 2410361430 @default.
- W2410361430 citedByCount "0" @default.
- W2410361430 crossrefType "journal-article" @default.
- W2410361430 hasAuthorship W2410361430A5001685490 @default.
- W2410361430 hasAuthorship W2410361430A5009943441 @default.
- W2410361430 hasAuthorship W2410361430A5033904438 @default.
- W2410361430 hasAuthorship W2410361430A5054282757 @default.
- W2410361430 hasAuthorship W2410361430A5073424133 @default.
- W2410361430 hasAuthorship W2410361430A5088390230 @default.
- W2410361430 hasConcept C10138342 @default.
- W2410361430 hasConcept C104317684 @default.
- W2410361430 hasConcept C120665830 @default.
- W2410361430 hasConcept C121332964 @default.
- W2410361430 hasConcept C126322002 @default.
- W2410361430 hasConcept C135763542 @default.
- W2410361430 hasConcept C159047783 @default.
- W2410361430 hasConcept C162324750 @default.
- W2410361430 hasConcept C185592680 @default.
- W2410361430 hasConcept C203014093 @default.
- W2410361430 hasConcept C2522874641 @default.
- W2410361430 hasConcept C2776178377 @default.
- W2410361430 hasConcept C2776408679 @default.
- W2410361430 hasConcept C2776455275 @default.
- W2410361430 hasConcept C2776461080 @default.
- W2410361430 hasConcept C2776999253 @default.
- W2410361430 hasConcept C2779149719 @default.
- W2410361430 hasConcept C2780040827 @default.
- W2410361430 hasConcept C2909179924 @default.
- W2410361430 hasConcept C54400483 @default.
- W2410361430 hasConcept C55493867 @default.
- W2410361430 hasConcept C61511704 @default.
- W2410361430 hasConcept C71924100 @default.
- W2410361430 hasConcept C90924648 @default.
- W2410361430 hasConceptScore W2410361430C10138342 @default.
- W2410361430 hasConceptScore W2410361430C104317684 @default.
- W2410361430 hasConceptScore W2410361430C120665830 @default.
- W2410361430 hasConceptScore W2410361430C121332964 @default.
- W2410361430 hasConceptScore W2410361430C126322002 @default.
- W2410361430 hasConceptScore W2410361430C135763542 @default.
- W2410361430 hasConceptScore W2410361430C159047783 @default.
- W2410361430 hasConceptScore W2410361430C162324750 @default.
- W2410361430 hasConceptScore W2410361430C185592680 @default.
- W2410361430 hasConceptScore W2410361430C203014093 @default.
- W2410361430 hasConceptScore W2410361430C2522874641 @default.
- W2410361430 hasConceptScore W2410361430C2776178377 @default.
- W2410361430 hasConceptScore W2410361430C2776408679 @default.
- W2410361430 hasConceptScore W2410361430C2776455275 @default.
- W2410361430 hasConceptScore W2410361430C2776461080 @default.
- W2410361430 hasConceptScore W2410361430C2776999253 @default.
- W2410361430 hasConceptScore W2410361430C2779149719 @default.
- W2410361430 hasConceptScore W2410361430C2780040827 @default.
- W2410361430 hasConceptScore W2410361430C2909179924 @default.
- W2410361430 hasConceptScore W2410361430C54400483 @default.
- W2410361430 hasConceptScore W2410361430C55493867 @default.
- W2410361430 hasConceptScore W2410361430C61511704 @default.
- W2410361430 hasConceptScore W2410361430C71924100 @default.
- W2410361430 hasConceptScore W2410361430C90924648 @default.
- W2410361430 hasIssue "3" @default.
- W2410361430 hasLocation W24103614301 @default.
- W2410361430 hasOpenAccess W2410361430 @default.
- W2410361430 hasPrimaryLocation W24103614301 @default.
- W2410361430 hasRelatedWork W118298973 @default.
- W2410361430 hasRelatedWork W1807414321 @default.
- W2410361430 hasRelatedWork W1993183790 @default.
- W2410361430 hasRelatedWork W1996352524 @default.
- W2410361430 hasRelatedWork W1998593536 @default.
- W2410361430 hasRelatedWork W2020081463 @default.
- W2410361430 hasRelatedWork W2022873444 @default.
- W2410361430 hasRelatedWork W2070924771 @default.
- W2410361430 hasRelatedWork W2084047059 @default.
- W2410361430 hasRelatedWork W2377696648 @default.
- W2410361430 hasVolume "154" @default.
- W2410361430 isParatext "false" @default.
- W2410361430 isRetracted "false" @default.
- W2410361430 magId "2410361430" @default.
- W2410361430 workType "article" @default.